CEO: “An agreement that benefits both the community and the sector, driving our growth and improving related healthcare performance.”
Rome — A historic and exclusive agreement for Italy has been signed between Meril Life Sciences, a multinational medical device company with annual revenues exceeding €1 billion, and Umbra Medical Italy, an Italian distributor of medical and surgical devices that, from its base in Abruzzo, is expanding into international markets.
The agreement covers the vascular and endovascular devices segment and comes at a key consolidation phase for the company. In 2025, Umbra Medical Italy recorded revenues double those of the previous financial year. This figure signals significant acceleration in a sector characterized by strong competition, centralized procurement, and growing attention to technological innovation.
“The agreement with Meril significantly expands Umbra Medical Italy’s product portfolio and strengthens our positioning as a structured operator in the distribution of technologies for the treatment of peripheral diseases,” said CEO Manuel Pantalone. “The product line included in the agreement offers solutions for both public and private hospital facilities, with a direct impact on hemodynamics and vascular surgery activities.
This partnership comes during a period of strong expansion for our company. In 2025, our revenues grew exponentially, allowing us to consolidate our presence in both national and international markets while strengthening our internal organization. The agreement with Meril represents a further step in our growth journey and enables us to offer internationally recognized technological solutions to the Italian healthcare system.
Thanks to this agreement, Umbra Medical Italy aims to further consolidate its presence in 2026 by strengthening its commercial network and enhancing collaboration with hospitals, centralized healthcare purchasing bodies, and sector operators, in line with a development model focused on structured growth and international partnerships.”
In the national vascular device market, the transaction results in a new distribution framework and an expanded product offering, while clinical quality, economic sustainability, and supply chain reliability remain central priorities for healthcare institutions.
